Trial Profile
Veliparib (ABT888) and Topotecan (Hycamtin) for Patients with Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer with Negative or Unknown BRCA Status
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms VeTo
- 09 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
- 24 Mar 2015 Planned End Date changed from 1 Apr 2015 to 1 Aug 2015, according to to ClinicalTrials.gov record.